Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy.

von Roemeling CA, Caulfield TR, Marlow L, Bok I, Wen J, Miller JL, Hughes R, Hazlehurst L, Pinkerton AB, Radisky DC, Tun HW, Kim YSB, Lane AL, Copland JA.

Oncotarget. 2017 Oct 6;9(1):3-20. doi: 10.18632/oncotarget.21545. eCollection 2018 Jan 2.

2.

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy.

Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, Wang Y, Wharen RE, Yun K, Bu G, Knutson KL, Kim BYS.

Nat Nanotechnol. 2017 Aug;12(8):763-769. doi: 10.1038/nnano.2017.69. Epub 2017 May 1.

PMID:
28459470
3.

Lessons from immuno-oncology: a new era for cancer nanomedicine?

Jiang W, Yuan H, Chan CK, von Roemeling CA, Yan Z, Weissman IL, Kim BYS.

Nat Rev Drug Discov. 2017 Jun;16(6):369-370. doi: 10.1038/nrd.2017.34. Epub 2017 Mar 17.

PMID:
28303024
4.

Corrigendum: Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes.

Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, Knight JA, Tun HW, Wharen RE, Jiang W, Kim BY.

Sci Rep. 2016 Aug 1;6:30663. doi: 10.1038/srep30663. No abstract available.

5.

Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes.

Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, Knight JA, Tun HW, Wharen RE, Jiang W, Kim BY.

Sci Rep. 2016 May 19;6:26269. doi: 10.1038/srep26269. Erratum in: Sci Rep. 2016 Aug 01;6:30663.

6.

Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.

Yushi Q, Li Z, Von Roemeling CA, Doeppler H, Marlow LA, Kim BY, Radisky DC, Storz P, Copland JA, Tun HW.

Oncotarget. 2016 May 31;7(22):32156-71. doi: 10.18632/oncotarget.8537.

7.

Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.

von Roemeling CA, Copland JA.

Expert Opin Ther Targets. 2016;20(2):159-66. doi: 10.1517/14728222.2016.1086341. Epub 2015 Sep 28. Review.

8.

Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.

von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2015 May;100(5):E697-709. doi: 10.1210/jc.2014-2764. Epub 2015 Feb 12.

9.

Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration.

Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, Copland JA.

Oncotarget. 2014 Jul 30;5(14):5320-34.

10.

Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.

von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW, Copland JA.

Cancer Res. 2014 Sep 1;74(17):4796-810. doi: 10.1158/0008-5472.CAN-14-0210. Epub 2014 Jun 24.

11.

Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma.

von Roemeling CA, Marlow LA, Kennedy WP, Kennedy GT, Copland JA, Menefee ME.

Am J Cancer Res. 2013 Aug 14;3(4):390-401. eCollection 2013.

12.

Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.

von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW, Copland JA.

Clin Cancer Res. 2013 May 1;19(9):2368-80. doi: 10.1158/1078-0432.CCR-12-3249. Epub 2013 Apr 30.

13.

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME, Tun HW, Colon-Otero G, Perez EA, Copland JA.

Mol Cancer Ther. 2012 Oct;11(10):2105-15. doi: 10.1158/1535-7163.MCT-11-0873. Epub 2012 Jul 23.

14.

Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.

Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun HW, Döppler HR, Storz P, Smallridge RC, Copland JA.

J Cell Sci. 2012 Sep 15;125(Pt 18):4253-63. doi: 10.1242/jcs.097428. Epub 2012 Jun 20.

15.

Pathway signature and cellular differentiation in clear cell renal cell carcinoma.

Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA.

PLoS One. 2010 May 18;5(5):e10696. doi: 10.1371/journal.pone.0010696.

16.

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA.

Oncogene. 2010 May 20;29(20):2905-15. doi: 10.1038/onc.2010.64. Epub 2010 Mar 8.

Supplemental Content

Loading ...
Support Center